Bank of America’s Acurx Pharmaceuticals ACXP Stock Holding History

Bank of America’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17	Closed	-$42	–	5702
2025 Q4	$42	Sell	17 -54	-76%	-$259	﹤0.01%	6989
2025 Q3	$304	Buy	71 +3	+4%	+$18	﹤0.01%	7668
2025 Q2	$689	Buy	68 +61	+871%	+$491	﹤0.01%	7602
2025 Q1	$55	Buy	7 +1	+17%	+$13	﹤0.01%	7958
2024 Q4	$95	Hold	6	–	–	﹤0.01%	7746
2024 Q3	$215	Buy	6 +1	+20%	+$42	﹤0.01%	7550
2024 Q2	$236	Buy	+5	New	+$220	﹤0.01%	7523
2024 Q1	–	Sell	-1	Closed	-$54	–	7679
2023 Q4	$54	Buy	+1	New	+$75	﹤0.01%	7490
2023 Q1	–	Sell	-1	Closed	-$40	–	7759
2022 Q4	$40	Buy	+1	New	+$66	﹤0.01%	7836
2022 Q1	–	Sell	-5	Closed	–	–	8210
2021 Q4	$0	Buy	+5	New	+$476	﹤0.01%	8168

Other funds holding ACXP

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Bank of America's ACXP Position: Q1 2026 in Review

Bank of America sold out of Acurx Pharmaceuticals (ACXP) in Q1 2026, closing a stake of 17 shares — an estimated $42 sold.

Bank of America first reported a position in ACXP in Q4 2021 and held it in 10 quarters. The position peaked at $689 in Q2 2025. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

Bank of America reported no remaining Acurx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bank of America sold 17 Acurx Pharmaceuticals shares in Q1 2026, an estimated $42.
Bank of America first reported a position in Acurx Pharmaceuticals in Q4 2021 and held it in 10 quarters.
Bank of America's Acurx Pharmaceuticals position peaked at $689 in Q2 2025.
21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.